ECPN Stock | News | Quote | Stock Forum | Wednesday, October

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
El Capitan Precious Metals, Inc. ECPN Company Overview 

Stock Message Board http://investorshangout.com/search?q=ECPN&...mp;yt1=Go!

Last Updated: Wednesday, October 9, 2013 10:23:49 PM

El Capitan Precious Metals, Inc. ECPN Current Price and Quotes
Last Price 0.075
Previous Close 0.06 Open 0.055
Daily Range 0.075 - 0.055 52wk Range 0.42 - 0.055
Volume 1,303,580 Dividend N/A
Average Vol (3m) 372,672 Yield N/A
El Capitan Precious Metals, Inc. ECPN
Company Information

8390 Via de Ventura
Suite F-110
Scottsdale, AZ 85254

Website: http://www.elcapitanpmi.com
Phone: 928-515-1942
Email: info@elcapitanpmi.com

El Capitan Precious Metals, Inc. ECPN
El Capitan Precious Metals, Inc. is a U.S. based mineral exploration company whose primary asset is a 100% interest in the El Capitan precious metals project, located in Lincoln County, New Mexico.

El Capitan Precious Metals, Inc. ECPN
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jun 30, 2013 10-Q
CIK 0001135202
Fiscal Year End 9/30
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 1000 - Metal Mining
Incorporated In: NV, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts

Arly Richau Secretary
Charles C. Mottley President, CEO
John F. Stapleton CFO
Company Directors

Charles C. Mottley
Arly Richau
John F. Stapleton
Company Notes

Formerly=DML Services, Inc. until 5-03
Service Providers

Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available

El Capitan Precious Metals, Inc. ECPN
ECPN Security Details

Share Structure

Market Value1 $15,543,489 a/o Oct 08, 2013
Shares Outstanding 259,058,143 a/o Aug 12, 2013
Float Not Available
Authorized Shares Not Available
Par Value  0.001
Shareholders

Shareholders of Record 1,451 a/o Dec 14, 2012
Security Notes

Capital Change=shs increased by 4 for 1 split. Ex-date=11/25/2002. Rec date=11/25/2002. Pay date=11/25/2002.
Capital Change=shs increased by 3 for 1 split. Ex-date=08/02/2004. Rec date=07/30/2004. Pay date=07/30/2004.
Short Selling Data

Short Interest 3,705 (-90.28%)
Sep 30, 2013
Significant Failures to Deliver  No
Transfer Agent(s)

Interwest Transfer Co., Inc.

El Capitan Precious Metals, Inc. ECPN Financials
Period Ending Sep 30, 2012 Sep 30, 2011 Sep 30, 2010 Sep 30, 2009
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses

Research and Development - - - -
Sales, General and Admin. 1,307 1,873 1,083 888
Non-Recurring Items 611 177,077 196 86
Other - - - -
Operating Income (1,918) (178,949) (1,279) (954)
Income From Continuing Operations

Add'l Income/Expense Items - 28 3 21
Earnings Before Interest and Tax (1,918) (178,921) (1,276) (952)
Interest Expense - - - 1
Earnings Before Tax (1,918) (178,921) (1,277) (954)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (1,918) (178,921) (1,274) (952)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (1,918) (178,921) (1,277) (954)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (1,918) (178,921) (1,277) (954)

El Capitan Precious Metals, Inc. ECPN Recent News

Sept 3, 2013 El Capitan Precious Metals Inc is Featured as the Daily Momentum Gainer to Watch on Smallcappower.com


ECPN El Capitan Precious Metals, Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=ECPN&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/ECPN/quote
Stock Chart http://www.otcmarkets.com/stock/ECPN/chart
Company Info http://www.otcmarkets.com/stock/ECPN/company-info
Recent News http://www.otcmarkets.com/stock/ECPN/news
Financials http://www.otcmarkets.com/stock/ECPN/financials
Filings and Disclosure http://www.otcmarkets.com/stock/ECPN/filings
Short Sales http://www.otcmarkets.com/stock/ECPN/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/ECPN/insider-transactions
Research Reports http://www.otcmarkets.com/stock/ECPN/research
Summary http://finance.yahoo.com/q?s=ECPN
Historical Prices http://finance.yahoo.com/q/hp?s=ECPN+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=ECPN
Basic Chart http://finance.yahoo.com/q/bc?s=ECPN+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=ECPN+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=ECPN+Headlines
Press Releases http://finance.yahoo.com/q/p?s=ECPN+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=ECPN+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=ECPN+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=ECPN+Industry
Major Holders http://finance.yahoo.com/q/mh?s=ECPN+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=ECPN+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=ECPN+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=ECPN
Balance Sheet http://finance.yahoo.com/q/bs?s=ECPN
Cash Flow http://finance.yahoo.com/q/cf?s=ECPN+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/ECPN
Market Watch http://www.marketwatch.com/investing/stock/ECPN
Bloomberg http://www.bloomberg.com/quote/ECPN:US
Morningstar http://quotes.morningstar.com/stock/s?t=ECPN
Bussinessweek http://investing.businessweek.com/research/st...icker=ECPN
Barchart http://www.barchart.com/quotes/stocks/ECPN
OTC Short Report http://otcshortreport.com/index.php?index=ECPN
Investopedia http://www.investopedia.com/markets/stocks/ECPN/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading